CPRX — Catalyst Pharmaceuticals Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $27.68
- 30-Day Move
- +14.5%
- Market Cap
- $3.0B
- Shares Outstanding
- 122,120,000
- P/E Ratio
- 14.07
- P/B Ratio
- 3.01
Catalyst Pharmaceuticals Inc
A read-only Alphactor snapshot forCatalyst Pharmaceuticals Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$27.68
30-Day Move
+14.5%
Market Cap
$3.0B
Shares Outstanding
122,120,000
P/E Ratio
14.07
P/B Ratio
3.01
$27.68
+14.5%last 90 delayed daily bars
90D High
$27.71
90D Low
$22.13
Avg Volume
1,281,780
Gross margin is running at 85.2%, which gives a quick read on operating quality before you open the full model.
Net margin is 36.4%, useful for comparing CPRX against peers in Biotechnology.
CPRX is up 14.5% over the last 30 trading days shown on this page.
Latest operating income is $62M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$54.75
Rule of 40
55.2%
Latest Close
$27.68
30-Day Move
+14.5%
Market Cap
$3.0B
Shares Outstanding
122,120,000
P/E Ratio
14.07
P/B Ratio
3.01
ROE
22.5%
ROA
19.4%
Gross Margin
85.2%
Operating Margin
43.8%
Net Margin
36.4%
Debt / Equity
0
Current Ratio
6.08
Latest Revenue
$153M
Revenue
$153M
Gross Profit
$127M
Operating Income
$62M
Net Income
$53M
Gross Margin
8519.0%
Net Margin
3639.0%
Current Ratio
6.08
Debt / Equity
0.00
Fair Value
$54.75
Upside / Downside
+97.8%
Signal
Undervalued
Implied Growth
-1.7%
DCF
$112.40
EPV
$21.96
EV/Rev
$29.90
Growth Assumption
40.1%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$209M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative growth / decline priced in
Altman Z
14.80
Safe
Piotroski
6
Moderate (4-6)
Cash Conversion
0.97x
Rule of 40
55.2%
Strong
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $214M | $102M | $83M | $116M |
| 2023-12-31 | $398M | $87M | $71M | $62M |
| 2024-12-31 | $492M | $195M | $164M | $239M |
| 2025-12-31 | $589M | $258M | $214M | $209M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
BlackRock
Filed 2024-08-13
$290M
--
Vanguard Group
Filed 2025-05-09
$206M
+0.8%
Renaissance Technologies
Filed 2025-05-14
$72M
--
Geode Capital Management
Filed 2026-02-09
$68M
+0.3%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.